Literature DB >> 30304731

First-Trimester Placental Growth Factor for the Prediction of Preeclampsia in Nulliparous Women: The Great Obstetrical Syndromes Cohort Study.

Amélie Boutin1, Suzanne Demers2, Cédric Gasse3, Yves Giguère4, Amélie Tétu1, Geneviève Laforest1, Emmanuel Bujold5,6.   

Abstract

BACKGROUND: First-trimester maternal serum markers have been associated with preeclampsia (PE). We aimed to evaluate the performance of first-trimester placental growth factor (PlGF) for the prediction of PE in nulliparous women. SUBJECTS AND METHODS: We conducted a prospective cohort study of nulliparous women with singleton pregnancy at 11-13 weeks. Maternal serum PlGF concentration was measured using B·R·A·H·M·S PlGFplus KRYPTOR automated assays and reported in multiple of the median adjusted for gestational age. We used proportional hazard models, along with receiver operating characteristic curves and areas under the curve (AUC).
RESULTS: Out of 4,652 participants, we observed 232 (4.9%) cases of PE including 202 (4.3%) term and 30 (0.6%) preterm PE. PlGF was associated with the risk of term (AUC = 0.61, 95% confidence interval [CI] 0.57-0.65) and preterm PE (AUC = 0.73, 95% CI 0.64-0.83). The models were improved with the addition of maternal characteristics (AUC for term PE 0.66, 95% CI 0.62-0.71; AUC for preterm PE 0.81, 95% CI 0.72-0.91; p < 0.01). At a false-positive rate of 10%, PlGF combined with maternal characteristics could have predicted 26% of term and 55% of preterm PE. The addition of pregnancy-associated plasma protein A did not significantly improve the prediction models.
CONCLUSION: First-trimester PlGF combined with maternal characteristics is useful to predict preterm PE in nulliparous women.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Antenatal screening; Biochemical markers; Biochemical screening; First trimester; Human fetus; Maternal serum screening; Placental growth factor; Preeclampsia; Prenatal screening

Mesh:

Substances:

Year:  2018        PMID: 30304731     DOI: 10.1159/000487301

Source DB:  PubMed          Journal:  Fetal Diagn Ther        ISSN: 1015-3837            Impact factor:   2.587


  3 in total

1.  Incidence and risk factors for Preeclampsia in a cohort of healthy nulliparous pregnant women: a nested case-control study.

Authors:  Jussara Mayrink; Renato T Souza; Francisco E Feitosa; Edilberto A Rocha Filho; Débora F Leite; Janete Vettorazzi; Iracema M Calderon; Maria H Sousa; Maria L Costa; Philip N Baker; Jose G Cecatti
Journal:  Sci Rep       Date:  2019-07-02       Impact factor: 4.379

2.  Clinical Application of Multi-Index Combined Risk Assessment in Early Pregnancy for Screening of Preeclampsia.

Authors:  Xiaohong Xu; Guoxiu Yan; Jijun Liu; Xuelei Li; Bin Zhang; Xianglian Meng; Hongbo Chen; Baoliang Han; Kun Shao; Xuefen Zhao; Jing Liu; Yan Yan
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-27       Impact factor: 2.650

3.  Beneficial effects of nicotinamide on the mouse model of preeclampsia.

Authors:  Phillip K Huynh; Nobuyuki Takahashi; Nobuyo Maeda-Smithies; Feng Li
Journal:  OA J Pregnancy Child Care       Date:  2018-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.